Liquidia (NASDAQ:LQDA) Receives Buy Rating from Needham & Company LLC

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 target price on the stock. Needham & Company LLC’s price target would suggest a potential upside of 46.89% from the stock’s previous close.

LQDA has been the topic of several other reports. Raymond James lifted their price objective on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a research note on Friday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Monday, May 12th. Oppenheimer lowered Liquidia from a “market perform” rating to an “underperform” rating and set a $13.00 price target on the stock. in a research report on Monday. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.56.

Liquidia Stock Down 0.1%

Shares of NASDAQ LQDA opened at $17.02 on Wednesday. The stock has a market capitalization of $1.45 billion, a PE ratio of -10.44 and a beta of 0.24. The firm has a fifty day moving average of $14.67 and a 200-day moving average of $13.48. Liquidia has a 52-week low of $8.26 and a 52-week high of $19.41.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Equities research analysts expect that Liquidia will post -1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 5,964 shares of the business’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the completion of the transaction, the general counsel now owns 570,301 shares in the company, valued at approximately $7,738,984.57. The trade was a 1.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,450 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the transaction, the insider now directly owns 263,152 shares of the company’s stock, valued at approximately $3,597,287.84. The trade was a 0.92% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,138 shares of company stock worth $450,233. Insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LQDA. JPMorgan Chase & Co. grew its position in Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after buying an additional 210,753 shares in the last quarter. DMC Group LLC raised its position in shares of Liquidia by 17.4% during the 4th quarter. DMC Group LLC now owns 16,302 shares of the company’s stock worth $192,000 after buying an additional 2,419 shares in the last quarter. Catalina Capital Group LLC lifted its stake in shares of Liquidia by 6.5% in the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock worth $215,000 after acquiring an additional 1,125 shares during the period. Rhumbline Advisers boosted its holdings in shares of Liquidia by 3.5% in the fourth quarter. Rhumbline Advisers now owns 80,652 shares of the company’s stock valued at $948,000 after acquiring an additional 2,741 shares in the last quarter. Finally, Sigma Planning Corp boosted its holdings in shares of Liquidia by 3.4% in the fourth quarter. Sigma Planning Corp now owns 65,210 shares of the company’s stock valued at $767,000 after acquiring an additional 2,115 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).